Collectively, these findings present a unique opportunity for testing in cancer clinical trials where FOXC1 expression status may be found to be useful in predicting efficacy of Perfenidone in ameliorating tumor growth and/or metastatic dissemination (Figure 4). The gene discussed is FOXC1; the disease is cancer.